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mABSTRACT
Background: Considerable clinical data on the
treatment of type 2 diabetes with incretin-based thera-
pies (glucagon-like peptide 1 receptor agonists [GLP-
1RAs] and dipeptidyl-peptidase IV [DPP-4] inhibitors)
are available.
Objective: This meta-analysis was performed to
support the understanding of the overall evidence by
summarizing the findings from studies of the incretin-
based therapies.
Methods: The MEDLINE, EMBASE, BIOSIS, and
BIOSIS trial databases were searched for relevant liter-
ature published between January 1, 1990, and June 30,
2011. Search terms included GLP-1, DPP-4, the
names of drugs that have been approved by the US
Food and Drug Administration for the treatment of
diabetes, and the names of drugs that have not been
approved but are in late-stage research. Studies were
included if they were randomized controlled trials of
12 to 52 weeks’ duration and having change from
baseline in hemoglobin (Hb) A1c as the primary end
oint. The random effects meta-analyses models exam-
ned HbA1c, fasting plasma glucose (FPG), and body
weight for individual therapies, but did not compare
effects between therapies.
Results: The reviewers identified 362 unique clinical
studies, of which 80 were eligible for inclusion in the
present meta-analysis. Mean baseline HbA1c values
anged from 7.4% to 10.3% (GLP-1RA studies) and
.2% to 9.3% (DPP-4 inhibitor studies). The highest
aintenance doses of the GLP-1RAs and the DPP-4
nhibitors were associated with changes from baseline
n mean HbA1c of 1.1% to 1.6% and 0.6% to
1.1%, respectively. Mean reductions in FPG with
exenatide once weekly (QW) or liraglutide once daily
were apparently greater than those with exenatide
twice daily (BID) and the DPP-4 inhibitors, with the
June 2012exception of vildagliptin. Mean weight losses with the
GLP-1RAs and the DPP-4 inhibitors were –2.0 and
0.2 to 0.6 kg, respectively. The limitations of the
resent analysis included a lack of adjustment for pla-
ebo use and interstudy heterogeneity associated with
ifferences in methodology (eg, management of con-
urrent medications, blinding, criteria for treatment
iscontinuation).
Conclusions: All of the incretin-based therapies in the
resent meta-analysis were associated with significant re-
uctions from baseline in HbA1c and FPG. Further direct
omparative studies between the GLP-1RAs and the
PP-4 inhibitors and within the GLP-1RA class are
ustified. (Clin Ther. 2012;34:1247–1258) © 2012 Elsevier
S Journals, Inc.
Key words: body weight, DPP-4 inhibitors, fasting
lasma glucose, GLP-1, hemoglobin A1c, incretin mi-
etics, meta-analysis, systematic review.
INTRODUCTION
Multiple. therapies that affect glucose homeostasis via
glucagon-like peptide (GLP)-1 signaling pathways are
now available for the treatment of type 2 diabetes mel-
litus.1 These incretin-based therapies are classified as
GLP-1 receptor agonists (GLP-1RAs) or dipeptidyl-
peptidase IV (DPP-4) inhibitors. GLP-1RAs adminis-
Earlier versions of the analyses in this article were presented in abstract
and poster format at the 46th Meeting of the European Association for
the Study of Diabetes; Stockholm, Sweden; September 20–24, 2010;
the abstract was published in Diabetologia. 2010;52(Suppl 1):S333. Ab-
stract: 836.
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Clinical Therapeuticstered at therapeutic concentrations directly activate the
GLP-1R, whereas DPP-4 inhibitors slow GLP-1 degra-
dation, thereby increasing endogenous GLP-1 concentra-
tions that activate GLP-1R.2,3 The potential glycemic
benefits of these treatments include glucose-dependent
stimulation of insulin production and secretion; sup-
pression of inappropriate glucagon secretion; slowing
of gastric emptying, which reduces the rate of glucose
appearance in the circulation; and satiety, which may
reduce food intake.3 The latter 2 mechanisms may be
responsible for the modest weight loss associated with
incretin-based therapies.3
There are key structural differences between various
GLP-1RAs and DPP-4 inhibitors. Amino acid back-
bones in GLP-1RAs resemble human GLP-1 (eg, lira-
glutide4) or exendin-4 (eg, exenatide), which shares
53% amino acid sequence identity with human GLP-
1.3,5 Liraglutide contains a fatty acid to improve in
vivo stability.4 The half-lives of GLP-1RAs range from
.4 hours (exenatide6) to 13 hours (liraglutide).4 Con-
tinuous release of once-weekly exenatide was achieved
by embedding exenatide in biodegradable micro-
spheres that release exenatide over 10 weeks.6 Among
he available GLP-1RAs, differences in structure, half-
ife, and plasma excursion of the active molecule may
ffect potential efficacy. Small-molecule DPP-4 inhibi-
ors also differ in molecular structure and mechanism:
logliptin, linagliptin, and sitagliptin are in the xan-
hine class that forms a noncovalent bond with DPP-4,
hereas saxagliptin and vildagliptin are cyanopyrroli-
ines that form a covalent bond with the active site ser-
ne.7 Nonetheless, all DPP-4 inhibitors reduce the degra-
ation of GLP-1.7 Because DPP-4 inhibitors have been
ssociated with increased endogenous concentrations of
umanGLP-1, theymay exert similar physiologic effects.
The comprehensive clinical trial programs for the
evelopment of GLP-1RAs and DPP-4 inhibitors pro-
ide extensive data on efficacy to inform evidence-
ased clinical decisions. The volume of available data
s difficult to synthesize and makes differences in meth-
dology difficult to assess, yet affords an opportunity
or a systematic review with the goal of providing phy-
icians with an overview of the available clinical evi-
ence. Evidence-based reviews are valuable for orga-
izing large amounts of published data, identifying
rends in treatment efficacy, and assisting in the cate-
orization of therapies (eg, as a metaclass [incretin-
ased therapies], as 2 classes [GLP-1RAs and DPP-4
nhibitors], or as 2 classes based on duration of ac-
1248ion [short-acting GLP-1RAs, long-acting GLP-1RAs,
nd DPP-4 inhibitors]).
METHODS
Data Sources and Literature Search
The MEDLINE, EMBASE, BIOSIS, and BIOSIS tri-
als databases were searched for English-language arti-
cles published from January 1, 1990, to June 30, 2011.
Unpublished studies were excluded. Prespecified
search terms were dipeptidyl peptidase-4 inhibitor, di-
peptidyl peptidase-IV inhibitor, DPP-4 inhibitor,
DPP4 inhibitor, DPP-IV inhibitor, exenatide, exendin,
byetta, liraglutide, victoza, taspoglutide, albiglutide,
GLP-1 receptor agonist, GLP-1 mimetic, GLP-1 ana-
logue, GLP-1 analog, glucagon-like peptide-1 receptor
agonist, glucagon-like peptide-1 mimetic, glucagon-
like peptide-1 analogue, glucagon-like peptide-1 ana-
log, sitagliptin, januvia, alogliptin, linagliptin, trad-
jenta, vildagliptin, saxagliptin, incretin mimetic,
AVE0010 (now referred to as lixisenatide), and albu-
gon. Titles, abstracts, study drug names, and subject
headings were searched. A search of these terms was
also conducted in the 2011 abstract databases from the
American Diabetes Association and the European As-
sociation for the Study of Diabetes. All of the records
identifiedwere stored in an electronic database (Procite
version 5.0.3, ISI ResearchSoft, Carlsbad, California),
which identified duplicate citations and allowed cita-
tions to be searched by key word and grouped for
analyses.
Study Selection
Studies included in these analyses were randomized
controlled trials (RCTs) of 12 weeks’ duration that
included 10 patients with type 2 diabetes per treat-
ment arm, reported change in hemoglobin (Hb) A1c as
the primary endpoint, and studied the effects of adding
a single drug (not multiple therapies) in a representa-
tive population. Therapies were included if Phase III
data were available as of June 30, 2011, and the high-
est effective maintenance dose was known. The analy-
sis focused on therapies or therapeutic combinations
approved for use in the United States or the European
Union or that were in post–Phase III development at
the time of the search.
Publications matching the prespecified criteria were
identified stepwise. After the exclusion of duplicate ci-
tations, the list was limited to RCTs in patients with
type 2 diabetes. The following article types were ex-
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V.R. Aroda et al.cluded: reviews, letters, opinions, or treatment guide-
lines; abstracts published before January 2011 or du-
plicate abstracts; experimental non-human studies;
studies in type 1 diabetes; studies in obesity in the ab-
sence of diabetes; studies of drug mechanism of action,
pharmacokinetics, or pharmacodynamics properties.
Potential references were screened for key words indi-
cating study design (eg, case, crossover, interim, exten-
sion, meta, pooled, model, simulation, real-world, ret-
rospective, subgroup) by a reviewer (M.B.D.), with
verification of the sorted reference citations by another
reviewer (T.D.). Studies were eliminated if no Phase III
data were available, only a nonapproved administra-
tion method or dose was studied, the protocol was
unclear, or data were missing. Because of the depen-
dence of efficacy on dose, data from treatment arms
were excluded if a dose was not approved or was not
included in Phase III trials. Doses selected are speci-
fied in Supplemental Appendix Table I in the online
version at http://dx.doi.org/10.1016/j.clinthera.
2012.04.013. The remaining studies were reviewed in-
dependently by 3 individuals (M.B.D., T.D., and Y.P.),
and ambiguous decisions were resolved by consulta-
tion with a fourth reviewer (J.R.; see Acknowledg-
ments). The final study list was assessed against pub-
lished reviews and meta-analyses to confirm
completeness.1,8 Analyses of therapies within each
lass are reported in alphabetical order for consis-
ency and fair balance.
Data Extraction
Mean baseline characteristics and demographic
data collected included duration of diabetes, age,
HbA1c, fasting plasma glucose (FPG), and body
eight (see Supplemental Appendix Table II in the
nline version at http://dx.doi.org/10.1016/j.clinthera.
012.04.013). In addition, mean and/or least-squares
LS) mean (95% CI) changes from baseline to study
ndpoint for HbA1c, FPG, and weight were extracted
rom each treatment arm but were not imputed if
ata were missing. Rates of adverse events were not
xtracted. Data entered into the statistical model
ere checked for accuracy against the original refer-
nces by 4 individuals (M.B.D., T.D., Y.P., and
.V.R. [see Acknowledgements]).
To assess study quality, studies were reviewed for
arameters such as discontinuation rate, medication
hanges prior to baseline assessment, baseline differ-
nces, blinding, and analysis methods (see Supplemen-
June 2012al Appendix Table III in the online version at http://
x.doi.org/10.1016/j.clinthera.2012.04.013). No
djustments were made for these parameters.
Statistical Analysis
Because the studies included varying dosing regi-
mens, 2 types of analysis were conducted. One in-
cluded the highest maintenance dose approved or
tested, and 1 included all doses approved for use or
tested in a Phase III trial (including titration doses with
lesser efficacy). In both analyses, weighted mean (SE)
differences from baseline were derived from multiple
treatment arms per study and then per drug. Missing
SDs or SEs were imputed from the pooled, nonmissing
SDs or SEs within studies of the same drug.9 Models
tested included fixed-effects, random-effects, and
Bayesian random-effects meta-regression models. The
extent of heterogeneity determined whether a fixed-
effects or random-effects model was used in the analy-
sis. Fixed-effects and random-effects models were used
with low and high levels of heterogeneity, respectively.
The Bayesian meta-regression model was used for de-
terminingwhether differences in baselineHbA1c signif-
cantly affected the magnitude of calculated changes in
bA1c. Mean baseline HbA1c was assessed as a mod-
lator in meta-regression models. Study heterogeneity
I2) was determined. Publication bias was assessed by
funnel plots, with the precision (1/SE) plotted against
the effect size.
RESULTS
Search Results and Study Characteristics
From the initial database search, 362 potentially rel-
evant publications were identified (Figure 1). For indi-
vidual characteristics of the 80 publications selected
for final analysis, see Supplemental Appendix Table I
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2012.04.013.
The majority of studies in these analyses (73/80)
were conducted during Phase III development, and
98% (78/80) were published in 2005 or later. Sixty-
five percent (52/80) were 24 to 30 weeks in duration,
9% (7/80) were 6 months in duration, and 85%
(68/80) included 90 patients per arm. In the ma-
jority of the studies (76% [61/80]), oral glucose-
lowering therapies were administered in combina-
tion with the agent of interest. Mean baseline HbA1c
values generally ranged between 8.0% and 8.6%,
and rates of discontinuation of active therapies were
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Clinical Therapeuticssimilar (see Supplemental Appendix Table II in the on-
ine version at http://dx.doi.org/10.1016/j.clinthera.
012.04.013). Key differences among the clinical
rial programs for individual drugs included number
f studies, number of patients per trial, number of
oses tested, proportion of double-blinded trials,
Relevant papers
identified (n = 362) Exc
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• 
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• 
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Studies identified for
detailed review (n = 225)
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• Liraglutide
 once daily (n = 11)
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Figure 1. Study flow. HbA1c  hemoglobin A1c. *Stund proportion of trials preceded by discontinuation
1250of prior oral glucose-lowering therapies (run-in ver-
sus add-on design) (Table). A high level of study
heterogeneity was identified among studies for each
incretin-based treatment assessed (see Supplemental
Appendix Table IV in the online version at http://
dx.doi.org/10.1016/j.clinthera.2012.04.013), suggesting
based on study design (n = 137)
or pooled analysis (n = 41)
l practice or retrospective studies (n = 31)
ion studies (n = 24)
tudies (n = 12)
up analysis (n = 14)
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Table. Selected characteristics of the studies for individual GLP-1R agonists and DPP-4 inhibitors included in the meta-analysis.
Class/Drug
No. of
Studiesa
Total ITT
Population
Active-Treatment
ITT Populationb Doses Studied Doses Not Studied
Background
Medication,c
% of Patients
Discontinuations
of Active
Treatment,
Range, % of
Patients
Prestudy
Medication
Change,d
% of Patients
GLP-1 receptor
agonists
Exenatide BID 19 7328 4038 5 and 10 ge BID 2.5 g BID 94.7 9.7–29.8 0
Exenatide QW 7 2210 842 2 mg QWe 0.8 mg QW 85.7 0–21.0 0
Liraglutide
once daily
11 6533 4178 0.6, 0.9, 1.2, and
1.8 mge once
daily
0.045, 0.1, 0.225, 0.3,
0.45, and 0.75 mg
once daily
72.7 4.5–35.5 54.5
DPP-4 inhibitors
Alogliptin 5 2503 1976 12.5 and 25 mge
once daily
— 60.0 6.7–37.4 20.0
Linagliptin 9 5177 3221 5 mg once dailye 1 and 10 mg once daily 66.7 5.8–15.2 77.8
Saxagliptin 7 3187 1566 5 mg once dailye 2.5, 10, 20, 40, and
100 mg once daily
57.1 9.4–35.8 14.3
Sitagliptin 23 10,893f 5274f 100 mg once
dailye
5, 12.5, 25, 50 mg
BID; 25, 50, 200 mg
once daily
60.9 2.7–56.9 60.9
Vildagliptin 6 3976 2497 50 mg once
daily,g 50 mg
BIDeh
10, 25 mg BID; 25,
100 mg once daily
83.3 11.2–21.5 0
BID  twice daily; DPP-4  dipeptidyl-peptidase IV; GLP-1 glucagon-like peptide 1; QW  once weekly.
aSome studies evaluated multiple drugs, and so were included in the overall for each drug studied; therefore, the total count of studies exceeds 80.
bAll GLP-1RA or DPP-4 inhibitor groups included in the analysis.
cConcurrent glucose-lowering therapy.
dIncluded discontinuation of oral glucose-lowering therapy and discontinuation with transition to a different glucose-lowering therapy or therapies (see Supplemental
Appendix Table III in the online version at http://dx.doi.org/10.1016/j.clinthera.2012.04.013).
eHighest maintenance dose.
fData unavailable in 3 studies.
gNot as monotherapy, only with a sulfonylurea.
hNot as monotherapy, only with metformin or a thiazolidinedione.
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Clinical Therapeuticsthe data. Funnel plots assessing the precision of the data
suggested an even distribution of mean values for the
parameters studied (data not shown), interpreted as min-
imal publication bias.
Efficacy Findings
On analysis of the pooled data, each incretin-based
therapy was associated with significant mean reduc-
tions from baseline in HbA1c. For the highest mainte-
ance dose studied (see Supplemental Appendix Table
in the online version at http://dx.doi.org/10.1016/
.clinthera.2012.04.013), the mean changes from base-
ine in HbA1c were apparently greater with the long-
cting GLP-1RAs than with the DPP-4 inhibitors
Figure 2A and see Supplemental Figures 1 to 4 in
he online version at http://dx.doi.org/10.1016/
.clinthera.2012.04.013). This apparent difference was
lso reported after adjustment for differences in base-
ine HbA1c (on Bayesian analysis, mean [95% CI]
hanges in HbA1c: exenatide BID, 1.08 [1.22 to
0.94]; exenatide QW,1.54 [1.73 to1.36]; lira-
lutide once daily,1.22 [1.39 to1.05]; alogliptin,
0.70 [0.90 to0.50]; linagliptin,0.60 [0.80 to
0.40]; saxagliptin,0.71 [0.89 to0.54]; sitaglip-
in, 0.70 [0.78 to 0.63]; and vildagliptin, 0.98
1.46 to0.52]). A difference in mean HbA1c reduc-
tions between the GLP-1RAs and the DPP-4 inhibitors
was also apparent at all doses approved or in late-stage
development (see Supplemental Appendix Table I in
the online version at http://dx.doi.org/10.1016/
j.clinthera.2012.04.013) (exenatide BID, 1.05
[1.19 to 0.92]; exenatide QW, 1.59 [1.70 to
1.48]; and liraglutide once daily, 1.21 [1.35 to
1.06] versus alogliptin, 0.65 [0.80 to 0.50];
linagliptin, 0.61 [0.75 to 0.46]; saxagliptin,
0.68 [0.78 to0.57]; sitagliptin,0.67 [0.75 to
0.60]; and vildagliptin, 0.98 [1.37 to 0.59]).
On pooled analysis, FPG was significantly reduced
rom baseline with all of the GLP-1RAs and DPP-4
nhibitors studied. Among the GLP-1RAs, the mean
hanges in FPGwere numerically greater with the long-
cting GLP-1RAs than with exenatide BID (Figure 2B).
he mean changes in FPG with the DPP-4 inhibitors
ere 0.97, 1.04, 0.73, 0.87, and 1.57
(alogliptin, linagliptin, saxagliptin, sitagliptin, and
vildagliptin, respectively) with vildagliptin demon-
strating a broad range of FPG reductions. Similar or
lesser changes in FPG were observed in the all-labeled-
dose analyses (mean [95% CI] changes in FPG [mmol/
1252L]: exenatide BID,1.12 [1.31 to0.92]; exenatide
QW, 2.12 [2.28 to 1.96]; liraglutide once daily,
1.71 [2.00 to 1.43]; alogliptin, 0.92 [1.24 to
0.59]; linagliptin, 1.04 [1.59 to 0.49]; saxa-
gliptin, 0.73 [0.95 to 0.50]; sitagliptin, 0.87
[0.98, 0.77]; and vildagliptin, 1.32 [2.01 to
0.62]).
Weight Effects
Effects on body weight differed among the GLP-
1RAs and the DPP-4 inhibitors in the pooled analysis
(Figure 2C). Short- and long-acting GLP-1RAs were
associated with significant reductions from baseline in
body weight, whereas DPP-4 inhibitors only were as-
sociated with a trend toward weight loss. Similar find-
ings were obtained when the effects of each dose on
body weight were studied (mean [95% CI] changes in
weight [kg]: exenatide BID, 1.94 [2.35 to 1.53];
exenatide QW, 2.41 [2.83 to 1.99]; liraglutide
nce daily,1.66 [2.43 to0.88]; alogliptin,0.27
0.87 to 0.34]; saxagliptin, 0.64 [1.11 to
0.16]; sitagliptin, 0.29 [0.61 to 0.03]; and
ildagliptin, 0.21 [0.84 to 0.42]).
DISCUSSION
The findings from the present meta-analysis suggest
potential differences between the GLP-1RAs and the
DPP-4 inhibitors in terms of clinical response for gly-
cemia and weight. With the exception of vildagliptin,
all of the DPP-4 inhibitors appeared to have been as-
sociated with similar mean decreases in HbA1c, FPG,
and body weight, with overlapping 95%CIs, across all
of the clinical trials assessed. In contrast, the responses
in mean HbA1c within the GLP-1RA class appeared to
iffer between therapies, with overlapping 95% CIs
etween exenatide BID and liraglutide once daily only.
ith respect to mean responses in FPG in the GLP-
RA class, the 95% CIs overlapped only with ex-
natide QW and liraglutide once daily. In contrast,
he mean responses in body weight appeared to have
een similar with all of the GLP-1RAs across trials.
he pattern of response for glycemic end points ap-
eared to differ between GLP-1RAs, and the DPP-4
nhibitors seem to have had greater uniformity of
esponse.
The reasons that the patterns of overall outcomes
or HbA1c, FPG, and weight appeared different be-
tween the 2 drug classes are a matter of speculation.
The responses across all DPP-4 inhibitors may have
Volume 34 Number 6
V.R. Aroda et al.been uniform because these agents have similar effects
on endogenous GLP-1 concentrations. In contrast, the
variability in mean HbA1c and FPG between the GLP-
1RAs may have been related to known differences in
Exenatide BID
Exenatide QW
Liraglutide
Alogliptin
Linagliptin
Saxagliptin
Sitagliptin
Vildagliptin
Exenatide BID
Exenatide QW
Liraglutide
Alogliptin
Linagliptin
Saxagliptin
Sitagliptin
Vildagliptin
Exenatide BID
Exenatide QW
Liraglutide
Alogliptin
Saxagliptin
Sitagliptin
Vildagliptin
–2.0
–2.5 –2.0 –1.5
–2.5–3.0 –2.0 –1.5 –1
–1.5
HbA1c Chang
FPG Change (m
Weight Chang
A
B
C
Figure 2. Overall mean changes from baseline in (A) h
and (C) weight with the use of glucagon-li
peptidase IV (DPP-4) inhibitors at the high
systemic review of the efficacy of incretin-bthe structure, dose, and pharmacokinetic properties
June 2012between each of the GLP-1RAs. Additional study is
needed to support or refute these hypotheses.
Direct comparative studies have evaluated the po-
tential differences in clinical outcomes among agents
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Clinical Therapeuticsclass and are notable. In a Phase IIIb, comparative,
head-to-head, 18-week study in 800 patients treated
with either saxagliptin or sitagliptin, similar reductions
in HbA1c (treatment difference, 0.09%) and FPG
(treatment difference, 0.30 mmol/L) were observed.10
No significant differences in proinsulin, C-peptide, or
HOMA-B measurements were noted between these 2
agents. Additional comparative studies of sitagliptin or
saxagliptin versus vildagliptin may be warranted.
Greater reductions in HbA1c and FPGwere found with
ildagliptin compared with the other DPP-4 inhibitors,
ith marked variability introduced primarily by a sin-
le trial.11
Several RCTs directly compared the efficacy of a
GLP-1RA and an DPP-4 inhibitor using endpoints re-
lated and not related to glycemia. A randomized, par-
allel-group trial compared treatment with liraglutide
1.2 or 1.8 mg once daily to sitagliptin 100 mg once
daily over 26 weeks and reported findings on differ-
ences in HbA1c, FPG, and weight consistent with those
stimated in the present analysis. In that direct com-
arison of liraglutide and sitagliptin, significant differ-
nces in HbA1c (0.6%), FPG (1.3%), and weight
2.4 kg) between highest maintenance doses were re-
orted.12 Furthermore, differences in -cell function
etween a GLP-1RA and an DPP-4 inhibitor were re-
orted in that study, in a 4-week crossover study, and
n an 8-week crossover study.12–14 The first study re-
ported significantly greater fasting C-peptide concen-
tration, proinsulin:insulin ratio, and HOMA-B (but
not HOMA-IR) with liraglutide than with sitaglip-
tin.12 The 4-week crossover comparison between ex-
natide BID and sitagliptin (N 61) reported a signif-
cant 1.5-fold higher index of insulin secretion and 0.9-
old lower secretion of postprandial glucagon in
atients treated for 2 weeks with exenatide BID com-
ared with sitagliptin.14 A difference in gastric empty-
ing between the 2 therapies was noted, with exenatide
slowing gastric emptying by 44% compared with sita-
gliptin. Similar findings were reported in the 8-week
crossover study, in which exenatide was associated
with greater effects on mean 24-hour glucose, post-
prandial glucose, postprandial glucagon, HOMA-B,
and caloric intake compared with sitagliptin.13 The
4-week crossover study reported a 4-fold difference in
the molar plasma concentration of GLP-1 or GLP-1RA
with exenatide BID versus sitagliptin (63.8 vs 15.1
pmol/L, respectively), which is a potential explanation
for the differences in efficacy.14
1254Differences within the GLP-1RA class appear to be
related to the timing, duration, and half-life of therapy.
The decreases in HbA1c and FPG were greater with
xenatide 2.0mgQWand liraglutide 1.8mg once daily
omparedwith those with exenatide BID in direct com-
arative studies,15,16 presumably reflecting the contin-
ous steady-state level of GLP-1 activity achieved with
hese agents, whereas short-acting exenatide BID was
ore efficacious in regulating postprandial glucose
ompared with either exenatide QW or liraglutide
nce daily, reflecting its premeal dosing, short half-life,
nd more rapid peak effect. Differentiation between
xenatide 2.0mgQWand liraglutide 1.8mg once daily
as examined in a 26-week, randomized, open-label,
arallel-group noninferiority clinical study in 911 pa-
ients with type 2 diabetes. That trial, published in
bstract format after June 30, 2011, reported greater
bA1c lowering (0.2%) and weight loss with once
daily liraglutide injections than with weekly exenatide
injections.17
A network meta-analysis estimated the comparative
efficacy of exenatide QW with that of liraglutide 1.2
mg once daily, the dosage recommended by National
Institute for Health and Clinical Excellence in the
United Kingdom.18 In that analysis, the differences in
bA1c between exenatide QW and liraglutide once
aily were calculated based on differences in HbA1c
with the common comparators insulin glargine and
exenatide BID. The estimated mean differences in
HbA1c between exenatide QW and liraglutide 1.2 and
1.8 mg once daily were 0.14% and 0.03%, respec-
tively. The investigators of that analysis concluded that
exenatide QW and both dosages of liraglutide were
similarly efficacious in lowering HbA1c.
Other published meta-analyses, including analyses
y Amori et al,1 Fakhoury et al,19 Shyangdan et al,20
and McIntosh et al,21 have evaluated GLP-1–based
therapies. However, some meta-analyses have been
limited to GLP-1RAs only,8,22 DPP-4 inhibitors
only,23,24 or oral therapies only25; others have focused
n specific subgroups (eg, exenatide added to oral ther-
pies [Pinelli et al26] and maximal doses [Pinelli and
Hurren27]). Because of the substantive increase in data
on GLP-1–based therapies, an updated analysis that
included newly developed therapies and expanded
data was warranted. The present analysis is timely
given the approval of 2 GLP-1RA and 4 DPP-4 inhib-
itors in recent years. Compared with previously pub-
lished meta-analyses of GLP-1–based therapies,1,19–21
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V.R. Aroda et al.the present analysis is more inclusive—in part due to
the accumulating data in this field—with evaluation of
8 therapies from 80 studies (through June 2011) versus
4 therapies from 29 studies (to May 20, 2007) in the
meta-analysis by Amori et al, 4 therapies from 38 stud-
ies (to July 2009) in the meta-analysis by Fakhoury et
al, 6 therapies from 28 studies (to July 2010) in the
meta-analysis by Shyangdan et al, and 5 therapies from
40 studies (to May 2009) in the meta-analysis by
McIntosh et al. Inclusion/exclusion criteria in the pres-
ent analysis were similar to those in the meta-analyses
by Amori et al and McIntosh et al, but the meta-anal-
ysis by Fakhoury et al included only blinded, placebo-
controlled trials and required 100 participants per
trial. Recently conducted studies were more likely to
compare 2 active treatments, to be more culturally and
nationally diverse than previous studies, and to be
Phase III rather than Phase II. In addition, in the pres-
ent analysis, study data were screened by dose for max-
imum concordance with clinical practice.
An important concern in assessing the collected
study data is heterogeneity in the standard procedures
for studying different drugs. Systematic bias may have
been introduced into studies of individual therapies as
a result of differences in sample size, study design,
blinding, and populations analyzed; treatment prior to
the study; background therapies; duration of treatment
with stable background therapy; previous treatment
failure; treatment duration; treatment dose; compara-
tors; and dropout rates. The use of a run-in design
associated with a recent medication change or an
add-in design has also been identified as a key meth-
odologic difference. Similarly, differences in the proto-
col regarding changes in other medications may have
affected the study findings. However, studies of a given
drug were likely conducted using similar processes.
The primary processes affecting comparability of gly-
cemic changes with different therapies were likely dif-
ferences in the methods of measuring HbA1c,
28 the pla-
ebo effect associated with enrollment in a clinical
tudy program, general medical care provided during
he trial, and patient management prior to measure-
ent of baseline HbA1c. Although documentation of
the former issues is difficult, discontinuation of previ-
ous therapies (with or without the addition of a new
therapy) before the measurement of baseline HbA1c
was reported in the majority of studies of liraglutide,
linagliptin, or sitagliptin. Changes in glucose-lowering
medications in the period immediately before random-
June 2012ization may have affected the magnitude of subsequent
changes in HbA1c. Glycemic responses in trials with
djustment in background therapies prior to baseline
bA1c measurement must be interpreted with caution.
Although safety profile tolerability endpoints were
ot addressed in the present meta-analysis, differences
n adverse events may have influenced clinical deci-
ions. Most of the adverse events reported with the
LP-1RAs (primarily gastrointestinal events, eg, nau-
ea, vomiting) were mild or moderate, and the rates of
ypoglycemia were low when treatment with GLP-
RAs was not combined with a sulfonylurea.29–33 In a
irect-comparative trial between the DPP-4 inhibitors
axagliptin and sitagliptin, no differences in tolerabil-
ty or serious adverse events were reported,10 and the
most common AEs were infections and headache.
However, differences in tolerability between a GLP-
1RA and a DPP-4 inhibitor were reported in 3 direct-
comparator trials.12,14,34 Discontinuation rates over
6 weeks with liraglutide 1.8 mg once daily were 2-
old those with liraglutide 1.2 mg once daily and sita-
liptin 100 mg.12 Nausea was transient in most cases
and was reported in 4-fold more patients with lira-
glutide 1.2 or 1.8 mg once daily than with sitagliptin.
Vomiting was twice as common with liraglutide, but
the rates of serious adverse events were similar. De-
Fronzo et al14 reported similar findings in a 4-week
rossover study that compared exenatide BID to sita-
liptin; transient nausea occurred 3-fold more fre-
uently with exenatide BID than with sitagliptin. Sim-
lar results were obtained in an 8-week crossover study
hat compared exenatide BID to sitagliptin: nausea and
omiting were 2- to 3-fold more common with ex-
natide BID treatment, but headache and diarrhea
ere observed at similar frequencies.13 In a study that
ompared clinical outcomes with exenatide QW and
itagliptin, nausea occurredmore than twice as often in
atients treated with exenatide as with sitagliptin, but
similar rate of serious adverse events was reported.34
Differences in tolerability between different GLP-1RAs
have also been reported. In DURATION-1 (Diabetes
Therapy Utilization: Researching Changes in A1C,
Weight and Other Factors Through Intervention With
Exenatide Once Weekly),16 which compared the effi-
cacy and safety profiles of exenatide BID and QW, the
prevalence of transient nausea appeared to have been
lower with exenatide QW than with exenatide BID
(26% vs 35%), although the prevalence of serious ad-
verse events was similar (5.4% vs 3.4%). In the
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Clinical TherapeuticsLEAD-6 (Liraglutide Effect Action in Diabetes) trial,15
which compared the efficacy and safety profiles of lira-
glutide 1.8 mg once daily with those of exenatide BID
10 g, the proportion of patients who experienced
nausea was similar (26% vs 28%). However, the inci-
dences of serious and severe adverse events appeared
be greater in liraglutide-treated patients (serious, 5.1%
vs 2.6%; severe, 7.2% vs 4.7% with liraglutide once
daily vs exenatide BID, respectively). In the DURA-
TION-6 study,17 which compared the efficacy and
afety profiles of exenatide QWwith liraglutide 1.8 mg
nce daily, both therapies were reported as having a
avorable safety profile.
Differences in the practical aspects of care were not
onsidered in the present analysis. The DPP-4 inhibi-
ors are orally administered 1 time per day, whereas
he GLP-1RAs are administered by subcutaneous in-
ection twice daily, once daily, or once every 7 days.
xenatide BID must be administered within 60 min-
tes before the 2 largest meals of the day,35 whereas the
iming of the administration of liraglutide once daily or
xenatide QW is flexible.15,16
Limitations of the present meta-analysis included
difficulty in capturing all relevant papers due to the
rapidly evolving evidence base, which led to selection
of a specific end-date. An additional limitation was
inadequate information to adjust the data for non–
study-drug related improvements in HbA1c, FPG, or
weight. As in clinical practice, the contributions to ef-
ficacy of improved lifestyle and/or positive treatment
expectations cannot be quantified. Because of increas-
ing interest in active comparators among the therapies
for type 2 diabetes, the ability to adjust data for a
placebo effect is diminishing.25 Only trial-level pub-
ished data (not subject-level data) were available for
he analyses in the present report.
CONCLUSIONS
All of the incretin-based therapies analyzed in the present
study were associated with reductions from baseline in
HbA1c and FPG. The findings emphasize a continued
eed for direct-comparative trials between GLP-1–based
herapies to further inform treatment decisions.
SUPPLEMENTAL MATERIAL
Supplemental appendixes and figures accompanying
this article can be found in the online version at
http://dx.doi.org/10.1016/j.clinthera.2012.04.013.
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peptide 1 receptor agonists (G
in type 2 diabetes mellitus.
Drug Highest Maintenance
GLP-1RAs
Exenatide BID 10 g BID
Exenatide QW 2 mg QW
Liraglutide 1.8 mg once dai
DPP-4 inhibitors
Alogliptin 25 mg once daily
Linagliptin 5 mg once daily
Saxagliptin 5 mg once daily
Sitagliptin 100 mg once da
Vildagliptin 50 mg BID*
*Not as monotherapy, only with a sulfonylurea.
†Not as monotherapy, only with metformin or a thiazolidineresent meta-analysis of the efficacy of the glucagon-like
LP-1RAs) and dipeptidyl-peptidase IV (DPP-4) inhibitors
Dose All Doses
5 and 10 g BID
2 mg QW
ly 0.6, 0.9, 1.2, and 1.8 mg once daily
12.5 and 25 mg once daily
5 mg once daily
5 mg once daily
ily 100 mg once daily
50 mg BID,* 50 mg once daily†
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Supplemental Table II. Studies included in the present meta-analysis of the efficacy of the glucagon-like peptide 1 receptor agonists (GLP-1RAs) and
dipeptidyl-peptidase IV (DPP-4) inhibitors in type 2 diabetes mellitus.
Study Phase
Study
Duration, wk
ITT
Population Female, % White, %
Diabetes
Duration, y
Baseline
HbA1c, %
Baseline
Weight, kg
Baseline
FPG, mmol/L
Therapy
Studied
Background
Therapy Control
Dropout
Rate, %
GLP-1RA: Exenatide BID
Bergenstal et al
(2009)1
IIIb 24 124 51.6 NG 8.6 10.2 96.6 10.9 10 g EBID MET  SFU — 29.8
124 51.6 NG 8.4 10.1 96.9 11.2 Biphasic INS Asp once daily EBID 16.1
124 52.4 NG 9.9 10.3 93.8 9.9 Biphasic INS Asp BID EBID 19.4
Bolli et al
(2010)2
III 24 373 NG 0 NG 8.05 94.5 9.87 10 g EBID MET  TZD EBID NG
384 NG 0 NG 8.08 93.2 9.91 10 mg/wk TASPO — NG
392 NG 0 NG 8.08 95.5 9.83 20 mg/wk TASPO — NG
Buse et al
(2004)3
III 30 129 42.6 59.7 6.6 8.6 95 10.0 10 g EBID SFU PBO 29.5
125 40.8 61.6 6.3 8.5 95 10.8 5 g EBID PBO 24.0
123 37.4 66.7 5.7 8.7 99 9.3 PBO — 39.8
DeFronzo et al
(2005)4
III 30 113 39.8 79.6 4.9 8.18 101 9.8 10 g EBID MET PBO 17.7
110 48.2 77.3 6.2 8.26 100 9.4 5 g EBID PBO 18.2
113 40.7 72.6 6.6 8.2 100 8.9 PBO — 21.2
Forti et al
(2008)5
III 12 190 58.4 41.0 8.5 8.4 82.7 10.9 10 g EBID at breakfast,
dinner
MET  SFU 
TZD
— 11.1
187 51.3 45.0 8.3 8.5 81.8 9.0 10 g EBID at lunch, dinner EBID at breakfast,
dinner
16.0
Gallwitz et al
(2011)6
III 26 181 NG NG 5 7.9 NG NG 10 g EBID MET 25.4
173 NG NG 5 7.9 NG NG INS Aspart 20.8
Gao et al
(2009)7
III 16 234 52.0 0 8 8.3 69.6 9.3 10 g EBID MET  SFU PBO 17.5
232 59.0 0 8 8.3 67.9 9.3 PBO 10.3
Heine et al
(2005)8
III 26 282 45.0 79.8 9.9 8.2 87.5 10.1 10 g EBID MET  SFU INS 19.1
267 43.4 80.5 9.2 8.3 88.3 10.4 INS glargine EBID 9.4
Kadowaki et al
(2009)9
III 12 40 25.0 0 11.9 8.1 71.1 8.9 PBO SFU  BG or
SFU  TZD
2.5
38* 29.7 0 14.8 8.0 64.9 9.4 2.5 g EBID PBO 8.1
37 32.4 0 11.3 7.9 65.6 9.1 5.0 g EBID PBO 10.8
38 37.8 0 9.6 7.9 70.3 9.3 10 g EBID PBO 16.2
Kadowaki et al
(2011)10
III 24 72 31.9 NG 11.6 8.2 69.1 9.1 10 g EBID SFU, SFU 
BG, or SFU 
TZD
PBO 27.4
72 31.9 NG 12.2 8.3 67.0 9.1 5 g EBID PBO 9.7
35 31.4 NG 12.4 8.1 70.3 8.9 PBO — 5.6
Kendall et al
(2005)11
III 30 241 40.7 66.4 8.7 8.5 98.0 9.9 10 g EBID MET  SFU PBO 17.8
245 40.8 69.0 8.7 8.5 97.0 10.1 5 g EBID PBO 15.9
247 44.1 68.4 9.4 8.5 99.0 10.0 PBO — 23.9
Liutkus et al
(2010)12
III 26 111 40 57 6.3 8.2 94.5 9.2 10 g EBID TZD MET PBO 14.0
54 43 61 6.4 8.3 92.6 9.0 PBO — 7.0
Moretto et al
(2008)13
III 24 78 38 72.0 2 7.8 86 8.5 10 g EBID D/E PBO 13.0
77 48.0 65.0 2 7.9 85 9.2 5 g EBID PBO 14.0
77 45.0 66.0 1 7.8 86 8.9 PBO — 12.0
Nauck et al
(2007)14
III 52 253 47.0 NG 9.8 8.6 85.5 11.1 10 g EBID MET  SFU INS 21.3
248 51.0 NG 10 8.6 83.4 11.3 Biphasic INS Asp BID 10.1
Sowa et al
(2010)15
III 24 72 NG NG NG NG NG NG 10 g EBID SFU MET 
TZD
PBO NG
72 NG NG NG NG NG NG 5 g EBID PBO NG
35 NG NG NG NG NG NG PBO — NG
Zinman et al
(2007)16
III 16 121 46.3 85.1 7.3 7.9 97.5 9.1 10 g EBID TZD MET PBO 28.9
112 42.9 82.1 8.2 7.9 96.9 8.8 PBO — 14.3
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Study Phase
Study
Duration, wk
ITT
Population Female, % White, %
Diabetes
Duration, y
Baseline
HbA1c, %
Baseline
Weight, kg
Baseline
FPG, mmol/L
Therapy
Studied
Background
Therapy Control
Dropout
Rate, %
GLP-1RA: Exenatide QW
Bergenstal et al
(2010)17
III 26 160 44 33 6 8.6 89 9.2 2 mg EQW MET — 21
166 48 30 5 8.5 87 9.1 100 mg SITA once daily — 13
165 52 39 6 8.5 88 9.1 45 mg PIO — 21
Blevins et al
(2011)18
III 24 123 45 55 7 8.4 94.3 9.3 10 g EBID D/E or MET 
SFU  TZD
— 22.8
129 40 63 7 8.5 97.0 9.6 2 mg EQW EBID 15.5
Cuddihy et al
(2011)19
III 26 248 NG NG NG NG NG NG 2 mg EQW D/E — NG
246 NG NG NG NG NG NG 2.5 mg MET once daily — NG
163 NG NG NG NG NG NG 45 mg PIO once daily — NG
163 NG NG NG NG NG NG 100 mg SITA once daily — NG
Diamant et al
(2010)20
III 26 113 48 82 8.0 8.3 91.2 9.9 2 mg EQW MET  SFU INS Glargine 10.3
100 45 85 8.3 8.3 90.6 9.7 INS glargine — 6.3
Drucker et al
(2008)21
III 30 147 49.0 73.0 6 8.3 102 9.2 10 g EBID D/E, MET,
SFU, TZD or 2
OADs
— 11.6
148 45.0 83.0 7 8.3 102 9.6 2 mg EQW EBID 13.5
Kim et al
(2007)22
II 15 15 33.0 60.0 4 8.3 110 9.3 2 mg EQW D/E MET PBO 0
16* 25.0 56.0 5 8.6 107 10.3 0.8 mg EQW PBO 0
14 64.0 64.0 4 8.6 101 10.2 PBO — 14.3
GLP-1RA: Exenatide QM
MacConell et al
(2011)23
II 20 26 43 80 4.7 8.6 92 10.4 5 mg EQM D/E or MET or
PIO or MET
PIO
EQW 10
28 23 94 6.5 8.4 101 10.1 8 mg EQM EQW 7
27 43 77 6.8 8.6 94 10.0 11 mg EQM EQW 7
29 33 93 5.9 8.6 101 10.4 2 mg EQW — 0
GLP-1RA: Liraglutide
Buse et al
(2009)24
III 26 233 51.0 93.0 8.5 8.2 93.1 9.8 1.8 mg LIRA once daily METSFU EBID 14.2
231 45.0 91.0 7.9 8.1 93 9.5 10 g EBID LIRA 19.5
Garber et al
(2009)25
III 52 251 53.0 80.0 5.2 8.3 92.5 9.3 1.2 mg LIRA once daily D/E GLIM 35.5
247 51.0 75.0 5.3 8.3 92.8 9.5 1.8 mg LIRA once daily GLIM 30.1
248 46.0 77.0 5.6 8.4 93.4 9.5 8 mg GLIM once daily — 38.7
Kaku et al
(2010)26
III 24 88 40 0 9.3 8.6 66.1 9.85 0.6 mg LIRA once daily SFU PBO 5.7
88 33 0 11.6 8.21 64.5 9.16 0.9 mg LIRA once daily PBO 4.5
88 35 0 10.1 8.45 66.7 9.48 PBO — 15.9
Madsbad et al
(2004)27†
II 12 30 33.3 NG 4.6 7.4 NG 10.8 0.6 mg LIRA once daily D/E PBO 6.7
28* 41.4 NG 6.1 7.4 NG 9.9 0.75 mg LIRA once daily PBO 7.1
29 31.0 NG 3.4 7.4 NG 9.7 PBO — 17.2
26* 37.0 NG 3.4 7.4 NG NG 1-4 mg/d GLIM PBO 0
26* 34.6 NG NG NG NG NG 0.045 mg LIRA once daily PBO 11.5
25* 36.0 NG NG NG NG NG 0.225 mg LIRA once daily PBO 12
27* 33.3 NG NG NG NG NG 0.45 mg LIRA once daily PBO 25.9
Marre et al
(2009)28
III 26 234 47.0 NG 6.5 8.5 81.6 9.7 1.8 mg LIRA once daily SFU PBO 9
228 55.0 NG 6.7 8.5 81.6 9.8 1.2 mg LIRA once daily PBO 14
233 46.0 NG 6.5 8.4 81.6 10.8 0.60 mg LIRA once daily PBO 10.7
114 53.0 NG 6.5 8.4 81.6 9.5 PBO — 27.2
231 53.0 NG 6.6 8.4 81.6 9.9 4 mg ROSI LIRA 16
(continued)
V
.R
.A
roda
et
al.
June
2012
1258.e7
Supplemental Table II (continued).
Study Phase
Study
Duration, wk
ITT
Population Female, % White, %
Diabetes
Duration, y
Baseline
HbA1c, %
Baseline
Weight, kg
Baseline
FPG, mmol/L
Therapy
Studied
Background
Therapy Control
Dropout
Rate, %
Nauck et al
(2009)29
III 26 242 41.0 88.0 8 8.4 88.6 10.1 1.8 mg LIRA once daily MET PBO 21.1
241 46.0 88.0 7 8.3 88.6 9.9 1.2 mg LIRA once daily PBO 18.3
242 38.0 84.0 7 8.4 88.6 10.2 0.60 mg LIRA once daily PBO 14.0
244 43.0 89.0 8 8.4 88.6 10.0 4 mg GLIM once daily LIRA 13.9
122 40.0 88.0 8 8.4 88.6 10.0 PBO — 39.3
Pratley et al
(2010)30
III 26 225 48 82 6.0 8.4 93.7 10.1 1.2 mg LIRA once daily MET SITA 24.9
221 48 87 6.4 8.4 94.6 9.9 1.8 mg LIRA once daily SITA 13.6
219 45 91 6.3 8.5 93.1 10.0 100 mg SITA once daily — 11.4
Russell-Jones
et al (2009)31
III 26 232 43.0 NG 9.2 8.3 85.5 9.1 1.8 mg LIRA once daily MET SFU PBO or INS 10.0
115 51.0 NG 9.4 8.3 85.7 9.4 PBO — 16.0
234 40.0 NG 9.7 8.2 85 9.1 INS glargine LIRA 6.0
Yang et al
(2011)32
III 16 231 45.9 0 7.4 8.5 68.6 9.8 0.6 mg LIRA once daily MET GLIM 12.6
233 45.1 0 7.5 8.6 67.4 9.5 1.2 mg LIRA once daily GLIM 23.2
234 46.2 0 7.2 8.6 68.2 9.9 1.8 mg LIRA once daily GLIM 26.1
231 41.6 0 7.8 8.5 68.2 9.6 4 mg GLIM once daily — 8.7
Zinman et al
(2009)33
III 26 178 49.0 83.0 9 8.6 NG 10.3 1.8 mg LIRA once daily MET  TZD PBO 14.0
178 43.0 81.0 9 8.5 NG 10.1 1.2 mg LIRA once daily PBO 7.8
177 38.0 84.0 9 8.4 NG 10.0 PBO — 18.0
DPP-4 inhibitor: Alogliptin
DeFronzo et al
(2008)34
III 26 133 46.8 (overall) 66.9 (overall) NG NG NG 9.6 12.5 mg ALO once daily D/E PBO 21.7 (overall)
131 NG NG NG NG NG 9.5 25 mg ALO once daily PBO NG
64 NG NG NG NG NG 9.7 PBO — NG
Fleck et al
(2009)35
III 26 164 NG NG 3.2P 8.8P NG 10.6P 25 mg ALO once daily D/E PIO NG
163 NG NG 3.2P 8.8P NG 10.6P PIO 30 mg once daily — NG
164* NG NG 3.2P 8.8P NG 10.6P 12.5 mg ALO once daily 
30 mg PIO/d
— NG
164* NG NG 3.2P 8.8P NG 10.6P 25 mg ALO once daily  30
mg PIO/d
— NG
Nauck et al
(2009)36
III 26 213 52.6 80.0 6 7.9 NG 9.4 12.5 mg ALO once daily MET PBO 8.0
210 45.7 76.0 6 7.9 NG 9.5 25 mg ALO once daily PBO 13.3
104 52.2 76.0 6 8.0 NG 9.9 PBO — 6.7
Pratley et al
(2009)37
III 26 203 45.3 69.5 7.8 8.1 NG NG 12.5 mg ALO once daily SFU PBO 24.6
198 50.0 71.2 7.6 8.1 NG NG 25 mg ALO once daily PBO 25.3
99 48.5 72.7 7.7 NG NG NG PBO — 37.4
Pratley et al
(2009)38
III 26 97 45.4 73.2 7.8 8 NG 9.5 PBO  PIO  SFU or MET — 14.4
197 44.7 72.6 7.7 8.1 NG 9.5 12.5 mg ALO  PIO PBO  PIO 12.7
199 37.2 76.4 7.4 8.0 NG 9.5 25 mg ALO  PIO PBO  PIO 10.6
DPP-4 inhibitor: Linagliptin
Del Prato et al
(2011)39
III 24 336 51.2 53.6 NG 8.0 78.5 9.1 5 mg LIN once daily D/E PBO 10.1
167 52.7 53.9 NG 8.0 79.2 9.2 PBO — 17.4
Forst et al
(2010)40
II 12 65* 44.6 99 6.9 8.2 92.5 10.1 1 mg LIN once daily MET PBO 20.0
66 43.9 100 7.3 8.5 90.7 10.5 5 mg LIN once daily PBO 15.2
66* 47.0 99 8.2 8.4 89.9 10.5 10 mg LIN once daily PBO 9.1
65* 36.9 99 6.7 8.2 90.5 10.0 1-3 mg GLIM once daily — 6.2
71 38.0 97 6.2 8.4 93.1 10.3 PBO — 19.7
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Supplemental Table II (continued).
Study Phase
Study
Duration, wk
ITT
Population Female, % White, %
Diabetes
Duration, y
Baseline
HbA1c, %
Baseline
Weight, kg
Baseline
FPG, mmol/L
Therapy
Studied
Background
Therapy Control
Dropout
Rate, %
Gallwitz et al
(2011)41
III 104 764 NG 0 NG NG NG NG 5 mg LIN once daily MET GLIM NG
755 NG 0 NG NG NG NG 1-4 mg D GLIM — NG
Gomis et al
(2011)42
III 24 259 41.3 74.5 NG 8.6 78.3 10.5 5 mg LIN once daily PIO PBO 5.8
130 34.6 74.6 NG 8.58 82.7 10.6 PBO — 14.6
Kawamori et al
(2010)43
III 12 159 NG 0 NG NG NG NG 5 mg LIN once daily D/E PBO NG
160 NG 0 NG NG NG NG 10 mg LIN once daily PBO NG
80 NG 0 NG NG NG NG PBO — NG
Kawamori et al
(2010)44
III 26 159 NG 0 NG NG NG NG 5 mg LIN once daily D/E VOGL NG
160 NG 0 NG NG NG NG 10 mg LIN once daily VOGL NG
162 NG 0 NG NG NG NG 0.2 mg TID VOGL — NG
Lewin et al
(2010)45
III 18 161 NG NG NG NG NG NG 5 mg LIN once daily SFU PBO NG
84 NG NG NG NG NG NG PBO — NG
Owens et al
(2010)46
III 24 793 NG NG NG NG NG NG 5 mg LIN once daily MET SFU PBO NG
265 NG NG NG NG NG NG PBO — NG
Taskinen et al
(2011)47
III 24 524 47 75 NG 8.09 82.2 9.4 5 mg LIN once daily MET PBO 7.5
177 43 79 NG 8.02 83.3 9.2 PBO — 7.9
DPP-4 inhibitor: Saxagliptin
Chacra et al
(2009)48
III 24 248 54.4 59.7 7.1 8.4 75.2 9.4 2.5 mg SAXA once daily GLY PBO  GLY 22.6
253 56.5 59.7 6.8 8.5 76.2 9.7 5 mg SAXA once daily PBO  GLY 22.9
267 53.9 56.9 6.8 8.4 75.6 9.7 PBO  7.5 mg GLY once
daily
— 34.1
DeFronzo et al
(2009)49
III 24 192 56.8 79.7 6.7 8.1 86 9.7 2.5 mg SAXA once daily MET PBO 22.9
191 46.1 83.2 6.4 8.1 87.3 10.0 5 mg SAXA once daily MET PBO 25.1
181* 47.5 79.6 6.3 8 87.8 9.8 10 mg SAXA once daily PBO 22.7
179 46.4 83.8 6.7 8.1 87.1 9.7 PBO — 37.4
Fonseca et al
(2011)50
III 18 138 NG NG NG NG NG NG 5 mg SAXA once daily D/E MET NG
144 NG NG NG NG NG NG MET — NG
Göke et al
(2010)51
IIIb 52 428 50.5 82.2 5.5 7.7 88.7 9.0 5 mg SAXA once daily MET GLIP 27.1
430 46.0 84.2 5.4 7.7 88.6 8.9 5-20 mg GLIP once daily — 25.3
Rosenstock
et al (2008)52
III 12 67 37.0 87.0 1.8median 8 93.1 9.1 PBO for low dose D/E — 17.9
55 60.0 85.0 1.0median 7.7 86.6 8.6 2.5 mg SAXA once daily PBO 12.7
47 47.0 87.0 0.8median 7.9 89.8 9.4 5 mg SAXA once daily PBO 21.3
63* 37.0 84.0 0.7median 8 92.4 9.4 10 mg SAXA once daily PBO 14.3
6 41* 44.0 80.0 0.3median 7.5 91.2 8.0 PBO for high dose — 14.6
44* 39.0 77.0 0.5median 7.8 92.2 8.5 100 mg SAXA once daily PBO 0
12 54* 30.0 87.0 1.7median 7.9 88.9 9.6 20 mg SAXA once daily D/E PBO 20.4
52* 42.0 92.0 1.3median 7.8 86.8 8.8 40 mg SAXA once daily PBO 13.5
Rosenstock
et al (2009)53
III 24 102 43.1 87.3 3.1 7.9 92.1 9.9 2.5 mg SAXA once daily D/E PBO 28.4
106 49.1 87.7 2.5 8 90.87 9.5 5 mg SAXA once daily PBO 35.8
95 50.5 83.2 2.3 7.9 86.56 9.5 PBO — 42.1
98* 54.1 81.6 2.3 7.8 89.3 9.9 10 mg SAXA once daily PBO 29.6
Scheen et al
(2010)54
IIIb 18 403 52.9 67.7 6.3 7.7 NG 8.86 5 mg SAXA once daily MET — 9.4
398 49.2 65.1 6.3 7.7 NG 8.89 100 mg SITA once daily — 6.0
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Study Phase
Study
Duration, wk
ITT
Population Female, % White, %
Diabetes
Duration, y
Baseline
HbA1c, %
Baseline
Weight, kg
Baseline
FPG, mmol/L
Therapy
Studied
Background
Therapy Control
Dropout
Rate, %
DPP-4 inhibitor: Sitagliptin
Arechavaleta
et al (2011)55
III 30 516 45.0 57.6 6.8 7.5 80.6 8.0 100 mg SITA once daily MET GLIM 9.3
519 46.2 57.4 6.7 7.5 82.0 8.1 1 mg once daily GLIM — 9.8
Aschner et al
(2006)56
III 24 238 42.9 51.3 4.4P 8.01 NG 9.5 100 mg SITA once daily D/E PBO 12.2
250* 53.2 52.8 4.4P 8.08 NG 9.7 200 mg SITA once daily PBO
253 48.6 50.2 4.4P 8.03 NG 9.8 PBO — 14.7
Aschner et al
(2010)57
III 24 528 52.0 NG 2.6 7.2 NG 7.9 100 mg SITA once daily D/E MET 11.6
522 56.0 NG 2.1 7.2 NG 7.9 1g BID MET — 14.4
Bergenstal et al
(2010)58
III 24 90 NG NG NG 8.03 91.1 NG PBO MET — NG
177 NG NG NG 7.94 92.5 NG 100 mg SITA once daily PBO NG
182* NG NG NG 7.55 93.6 NG 10 mg/wk TASPO PBO, SITA NG
187* NG NG NG 7.57 91.8 NG 20 mg/wk TASPO PBO, SITA NG
Charbonnel
et al (2006)59
III 24 464 44.2 63.1 6.2P 7.96 NG 9.4 100 mg SITA once daily MET PBO 10.4
237 40.5 67.1 6.2P 8.03 NG 9.6 PBO — 19.0
Fonseca et al
(2011)60
III 26 NG NG NG NG NG NG NG 100 mg SITA once daily MET  PIO PBO NG
NG NG NG NG NG NG NG PBO — NG
Goldstein et al
(2007)61
III 24 182* 51.1 47.8 4.5 8.9 NG 11.4 500 mg BID MET D/E PBO 15.9
182* 54.9 58.2 4.5 8.68 NG 10.9 1 g BID MET PBO 14.3
190* 44.7 53.7 4.5 8.79 NG 11.3 50 mg BID SITA  500 mg
BID MET
PBO 13.7
182* 57.7 52.2 4.5 8.76 NG 10.9 50 mg BID SITA  1 g BID
MET
PBO 9.9
176 47.2 46.0 4.5 8.68 NG 10.9 PBO — 27.8
179 48.0 52.0 4.5 8.87 NG 11.2 100 mg SITA once daily PBO 20.7
Hanefeld et al
(2007)62
II 24 111 36.9 78.4 3.3 7.59 NG 9.7 PBO D/E — 27.0
110 54.5 85.7 3.3 7.6 NG 9.4 50 mg SITA once daily PBO 5.5
110 44.5 88.2 3.6 7.78 NG 9.8 100 mg SITA once daily PBO 16.4
111 55.9 81.1 4.5 7.79 NG 9.5 50 mg BID SITA PBO 9.9
111 48.6 88.3 3.6 7.71 9.7 25 mg SITA once daily PBO 13.6
Hermansen
et al (2007)63
III 24 222 47.3 61.3 8.3 8.34 86.5 10.0 100 mg SITA once daily SFUMET PBO 16.7
219 46.6 63.9 9.3 8.34 85.9 10.1 PBO SFU MET — 18.3
106* 47.2 57.5 7.2 8.42 85.8 10.1 100 mg SITA once daily SFU PBO 21.7
116* 47.4 64.7 9.3 8.27 87.2 10.0 100 mg SITA once daily SFUMET PBO 12.1
106* 45.3 55.7 8 8.43 85.1 10.3 PBO SFU — 17.9
113* 47.8 71.7 10.6 8.26 86.7 9.9 PBO SFU MET — 18.6
Iwamoto et al
(2010)64
III 12 80 31.5 0 6.4 7.74 NG 8.7 25 mg SITA once daily D/E PBO 3.8
72 36.3 0 4.7 7.49 NG 8.1 50 mg SITA once daily PBO 1.4
70 34.7 0 5.6 7.57 NG 8.0 100 mg SITA once daily PBO 2.9
68* 48.6 0 5.4 7.56 NG 7.9 200 mg SITA once daily PBO 1.5
73 41.2 0 5.1 7.65 NG 8.2 PBO — 6.8
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Supplemental Table II (continued).
Study Phase
Study
Duration, wk
ITT
Population Female, % White, %
Diabetes
Duration, y
Baseline
HbA1c, %
Baseline
Weight, kg
Baseline
FPG, mmol/L
Therapy
Studied
Background
Therapy Control
Dropout
Rate, %
Mohan et al
(2009)65
III 18 352 43.0 0 2.1 8.7 66.8 10.5 100 mg SITA once daily D/E PBO 13.0
178 40.0 0 1.9 8.8 66.6 10.5 PBO — 25.0
Nauck et al
(2007)66
III 52 588 42.9 73.5 6.5 7.48 89.5 8.8 100 mg SITA once daily MET GLIP 34.4
584 38.7 74.3 6.2 7.52 89.7 8.8 5–20 mg/d GLIP SITA 29.5
Nonaka et al
(2008)67
II 12 75 40.0 0.0 4 7.54 NG 9.1 100 mg SITA D/E PBO 2.7
76 34.0 0.0 4.1 7.69 NG 9.1 PBO — 11.8
Raz et al
(2006)68
III 18 103 37.3 61.8 4.5P 8.05 NG 10.2 PBO D/E — 17.3
193 46.3 69.3 4.5P 8.04 NG 10.0 100 mg SITA once daily PBO 8.3
199* 49.5 70.9 4.5P 8.14 NG 10.2 200 mg SITA once daily PBO 10.7
Raz et al
(2008)69
III 30 94 58.5 47.0 7.3 9.1 81.2 11.0 PBO MET — 14.9
96 49.0 42.0 8.4 9.3 81.5 11.2 100 mg SITA once daily PBO 17.7
Rosenstock
et al (2006)70
III 24 175 46.9 72.6 6.1 8.05 90.9 9.3 100 mg SITA once daily PIO PBO 14.9
178 42.1 72.5 6.1 8 86.4 9.2 PBO — 11.2
Rosenstock
et al (2011)71
II 12 NG* NG NG NG NG NG NG PBO1 MET — NG
NG* NG NG NG NG NG NG 1 mg BI once daily PBO1 NG
NG* NG NG NG NG NG NG 5 mg BI once daily PBO1 NG
NG* NG NG NG NG NG NG 10 mg BI once daily PBO1 NG
NG* NG NG NG NG NG NG 25 mg BI once daily PBO1 NG
NG* NG NG NG NG NG NG 50 mg BI once daily PBO1 NG
NG NG NG NG NG NG NG PBO2 — NG
NG NG NG NG NG NG NG 100 mg SITA once daily PBO2 NG
Scott et al
(2008)72
III 18 94 45 61.0 4.9 7.75 83.1 8.7 100 mg SITA once daily MET PBO 10.0
87 37.0 59.0 4.6 7.73 84.9 8.7 100 mg ROSI once daily PBO 2.0
92 41.0 61.0 5.4 7.68 84.6 8.9 PBO — 9.0
Seck et al
(2010)73
III 104 248 42.7 77.4 5.8 7.3 88.5 8.4 100 mg SITA once daily MET GLIP 56.9
256 37.1 78.5 5.7 7.3 90.3 8.5 5-20mg GLIP once daily — 54.2
Yang et al
(2011)74
III 24 NG NG 0 NG NG NG NG 100 mg SITA once daily MET PBO NG
NG NG 0 NG NG NG NG PBO — NG
DPP-4 inhibitor: Vildagliptin
Bolli et al
(2008)75
III 24 295 35.9 81.9 6.4 8.6 91.6 11.0 50 mg BID VILDA MET PIO 11.2
281 38.3 82.4 6.4 8.5 92 11.0 30 mg/d PIO VILDA 13.2
Bosi et al
(2007)76
III 24 143 42.7 74.1 6.8 8.4 92.5 9.7 50 mg VILDA once daily MET PBO 13.6
143 38.5 74.1 5.8 8.4 95.3 9.9 50 mg BID VILDA PBO 15.1
130 46.9 73.1 6.2 8.3 94.8 10.1 PBO — 16.5
Bosi et al
(2009)77
II 24 292* 42.0 73.9 1.9 8.7 90 10.8 50 mg BID VILDA  1000
mg BID MET
D/E MET 11.9
290* 44.1 73.1 1.9 8.6 87 10.2 50 mg BID VILDA  500 mg
BID MET
MET 15.5
297 40.0 75.0 2.1 8.7 88 10.3 50 mg BID VILDA MET 18.3
292 41.8 72.1 2.2 8.6 88 10.5 1000 mg MET once daily — 17.2
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Study Phase
Study
Duration, wk
ITT
Population Female, % White, %
Diabetes
Duration, y
Baseline
HbA1c, %
Baseline
Weight, kg
Baseline
FPG, mmol/L
Therapy
Studied
Background
Therapy Control
Dropout
Rate, %
Filozof and
Gautler
(2010)78
III 52 513 47.8 78.9 6.4 8.5 85.7 10.8 50 mg BID VILDA MET GLIC 20.7
494 48.2 77.5 6.8 8.5 84.2 10.6 320 mg GLIC once daily — 16.6
Garber et al
(2007)79
III 24 124 45.2 83.9 4.7 8.6 NG 10.3 50 mg VILDA once daily TZD PBO 15.6
136 55.1 79.4 4.6 8.7 NG 10.0 50 mg BID VILDA PBO 21.5
138 49.3 78.3 4.8 8.7 NG 10.1 PBO — 19.0
Garber et al
(2008)80
III 24 132 40.9 68.9 6.9 8.5 91.5 10.5 50 mg VILDA once daily SFU PBO 14.4
132 40.2 70.5 6.7 8.6 87.3 10.5 50 mg BID VILDA SFU PBO 15.9
144 41.7 67.4 7.8 8.5 89.4 10.3 PBO SFU — 25.0
ALO alogliptin; Asp aspart; BG biguanide; BI SGLT-2 inhibitor BI-10773; D/E diet and exercise; EBID exenatide BID; EQM exenatide once monthly; EQW exenatide once weekly; GLIC gliclazide;
GLIM glimepiride; GLIP glipizide; GLY glyburide; INS insulin; LIN linagliptin; LIRA liraglutide; METmetforming; NG not given; OAD oral antidiabetes drug; P pooled; PBO, placebo; PIO
pioglitazone; PBO placebo; QM once monthly; QW once weekly; ROSI rosiglitazone; SAXA saxagliptin; SFU any sulfonylurea; SITA sitagliptin; TASPO taspoglutide; TZD any thiazolidinedione;
VILDA  vildagliptin; VOGL  voglibose.
*Data row excluded from analysis.
†Study excluded from analysis of highest maintenance dose.
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Supplemental Table III. Comparison of designs of the studies included in the present meta-analysis of the efficacy of the glucagon-like peptide 1
receptor agonists (GLP-1RAs) and dipeptidyl-peptidase IV (DPP-4) inhibitors in type 2 diabetes mellitus.
Study
Washout/Rx
Change Prior to
Randomization?
Differences in
Baseline
Data?
Missing
Baseline Data Double-Blind?
Multi-National?
(Country or No.
of Countries)
Superiority or
Noninferiority Trial?
Missing
Weight Data Analysis Population Data Type
GLP-1RA: Exenatide BID
Bergenstal et al
(2009)1
N N N N N (US) Both N ITT & PP Mean
Bolli et al (2010)2 N N Y N Y (NG) NI N ITT LS mean
Buse et al (2004)3 N N N Y N (US) S N ITT & evaluable Mean
DeFronzo et al
(2005)4
N N N Y N (US) S N ITT & evaluable Mean
Forti et al (2008)5 N N N Y Y (2) NI N PP LS mean
Gallwitz et al
(2011)6
N N Y N N (Germany) NI N ITT LS mean
Gao et al (2009)7 N N N Y Y (4) S N ITT & PP LS mean
Heine et al (2005)8 N N N N Y (13) NI N ITT & PP LS mean
Kadowaki et al
(2009)9
N N N N N (Japan) S N ITT Mean
Kadowaki et al
(2011)10
N N Y Y N (Japan) S N ITT LS mean
Kendall et al
(2005)11
N N N Y N (US) S N ITT & evaluable Mean
Liutkus et al
(2010)12
N N N Y Y (5) S N ITT LS mean
Moretto et al
(2008)13
N N N Y Y (23) S N ITT LS mean
Nauck et al
(2007)14
N N Y (race) N Y (13) NI N ITT & PP Mean
Sowa et al (2010)15 N N Y Y N (Japan) S Y ITT LS mean
Zinman et al
(2007)16
N N N Y Y (3) S N ITT & PP Mean
GLP-1RA: Exenatide QW
Bergenstal et al
(2010)17
N N N Y Y (3) S N ITT LS mean
Blevins et al
(2011)18
N N N N N (US) NI N ITT LS mean
Cuddihy et al
(2011)19
N N Y N Y (NG) S Y ITT LS mean
Diamant et al
(2010)20
N N N N Y (7) S N ITT LS mean
Drucker et al
(2008)21
N N N N NG NI N ITT & evaluable LS mean
Kim et al (2007)22 N Y (sex) N Y N (US) S N ITT Mean
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Study
Washout/Rx
Change Prior to
Randomization?
Differences in
Baseline
Data?
Missing
Baseline Data Double-Blind?
Multi-National?
(Country or No.
of Countries)
Superiority or
Noninferiority Trial?
Missing
Weight Data Analysis Population Data Type
GLP-1RA: Exenatide QM
MacConell et al
(2011)23
N N N N NG S N ITT & evaluable LS mean
GLP-1RA: Liraglutide
Buse et al (2009)24 N N N N Y (15) Both N ITT & PP Mean
Garber et al
(2009)25
N N N Y Y (2) Both N ITT Mean
Kaku et al (2010)26 N N N Y N (Japan) S N ITT & PP Mean
Madsbad et al
(2004)27
Y (4-wk OAD washout) N Y (race) Y Y (2) S N ITT Adj mean
Marre et al
(2009)28
Y (2–4-wk transition to
GLIM)
N N N N (US) Both N ITT LS mean
Nauck et al
(2008)29
Y (3-wk transition to
MET)
N Y (race) Y Y (21) Both N ITT Mean
Pratley et al
(2010)30
N N N Y Y (13) Both N ITT & PP Mean
Russell-Jones et al
(2008)31
Y (6-wk transition to
MET & GLIM)
N Y (race) Y Y (17) Both N ITT Mean
Yang et al (2011)32 Y N N Y Y (3) Both Y ITT Mean
Zinman et al
(2009)33
Y (6–9-wk PIO to ROSI,
MET)
N Y (weight) Y Y (2) S N ITT Mean
DPP-4 inhibitor: Alogliptin
DeFronzo et al
(2008)34
N N Y (weight,
FPG,
diabetes
duration)
Y Y (16) S N ITT LS mean
Fleck et al
(2009)35*
N N N Y Y (NG) S N ITT LS mean
Nauck et al
(2009)36
N N N Y Y (15) S N ITT LS mean
Pratley et al
(2009)37
N N N Y N (US) S N ITT LS mean
Pratley et al
(2009)38
Y (transition from ROSI
to PIO)
N N Y Y (4) S N ITT LS mean
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Supplemental Table III (continued).
Study
Washout/Rx
Change Prior to
Randomization?
Differences in
Baseline
Data?
Missing
Baseline Data Double-Blind?
Multi-National?
(Country or No.
of Countries)
Superiority or
Noninferiority Trial?
Missing
Weight Data Analysis Population Data Type
DPP-4 inhibitor: Linagliptin
Del Prato et al
(2011)39
Y N Y Y Y (11) S Y ITT & PP Adj mean
Forst et al
(2010)40
Y N N Y Y (6) S Y ITT Mean
Gallwitz et al
(2011)41
N N Y Y Y (NG) NI N ITT & PP Adj mean
Gomis et al
(2011)42
Y N Y Y Y (7) S N ITT Adj mean
Kawamori et al
(2010)43
Y N Y Y N (Japan) S Y ITT Adj mean
Kawamori et al
(2010)44
Y N Y Y N (Japan) S Y ITT Adj mean
Lewin et al
(2010)45
Y N Y Y NG NI Y ITT Adj mean
Owens et al
(2010)46
N N Y Y NG S Y ITT Adj mean
Taskinen et al
(2011)47
Y N Y Y Y (10) S N ITT Adj mean
DPP-4 inhibitor: Saxagliptin
Chacra et al
(2009)48
Y (4-wk transition to
GLY)
N N Y Y (NG) S Y ITT Adj mean
DeFronzo et al
(2009)49
N N N Y Y (9) S Y PP LS mean & Adj
mean
Fonseca et al
(2011)50
N N Y Y NG S Y ITT Adj mean
Göke et al (2010)51 N N N Y Y (11) NI N PP Adj mean
Rosenstock et al
(2008)52
N N N Y N (US) S N Modified ITT Adj mean
Rosenstock et al
(2009)53
N Y (weight,
BMI, sex)
N Y NG S N ITT Adj mean
Scheen et al
(2010)54
N N Y Y Y (9) NI Y ITT & PP Adj mean
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Supplemental Table III (continued).
Study
Washout/Rx
Change Prior to
Randomization?
Differences in
Baseline
Data?
Missing
Baseline Data Double-Blind?
Multi-National?
(Country or No.
of Countries)
Superiority or
Noninferiority Trial?
Missing
Weight Data Analysis Population Data Type
DPP-4 inhibitor: Sitagliptin
Arechavaleta et al
(2011)55
N N N Y NG NI N ITT & PP LS mean
Aschner et al
(2006)56
Y (2–12-wk OAD
washout)
N N Y Y (18) S N ITT (all patients treated) LS mean
Aschner et al
(2010)57
N N Y Y Y (23) NI Y PP LS mean
Bergenstal et al
(2010)58
N N Y N Y (NG) S N ITT Mean
Charbonnel et al
(2006)59
Y (2–19-wk OAD
washout)
N N Y Y (25) S N ITT (all patients treated) LS mean
Fonseca et al
(2011)60
N N Y Y NG S Y ITT Mean
Goldstein et al
(2007)61
Y (2–12-wk OAD
washout)
N N Y Y (17) S N ITT (all patients treated) LS mean
Hanefeld et al
(2007)62
Y (2–6-wk OAD
washout)
Y (sex) N Y Y (NG) S N ITT (all patients treated)
& PP
Mean
Hermansen et al
(2007)63
Y (2–10 wk OAD
washout)
N N Y Y (NG) S N ITT (all patients treated) LS mean
Iwamoto et al
(2010)64
Y N Y Y N (Japan) S Y ITT LS mean
Mohan et al
(2009)65
Y (3–6-wk OAD
washout)
N N Y Y (3) S N Full analysis set LS mean
Nauck et al
(2007)66
Y (8 wk transition to
MET)
N N Y Y (31) NI N PP LS mean
Nonaka et al
(2008)67
Y (2–8-wk OAD
washout)
N N Y N (Japan) S N ITT (all patients treated) LS mean
Raz et al (2006)68 Y (2–12-wk OAD
washout)
N N Y Y (7) S N ITT (all patients treated) LS mean
Raz et al (2008)69 Y (6-wk transition to
MET)
N N Y Y (NG) S N Full analysis set LS mean
Rosenstock et al
(2006)70
Y (2–14-wk OAD
washout)
N N Y Y (15) S N ITT (all patients treated) LS mean
Rosenstock et al
(2011)71
N N Y Y Y (NG) S Y ITT Mean
Scott et al (2008)72 N N N Y Y (6) S N ITT (all patients treated) LS mean
Seck et al (2010)73 Y N N Y NG NI N PP LS mean
Yang et al (2011)74 Y Y Y Y N (China) S Y ITT LS mean
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Supplemental Table III (continued).
Study
Washout/Rx
Change Prior to
Randomization?
Differences in
Baseline
Data?
Missing
Baseline Data Double-Blind?
Multi-National?
(Country or No.
of Countries)
Superiority or
Noninferiority Trial?
Missing
Weight Data Analysis Population Data Type
DPP-4 inhibitor: Vildagliptin
Bolli et al (2008)75 N N N Y Y (9) NI N PP Adj mean
Bosi et al (2007)76 N N N Y Y (4) S N ITT Adj mean
Bosi et al (2009)77 N N N Y Y (5) S N ITT LS mean
Filozof and Gautier
(2010)78
N N N Y NG NI N ITT & PP Mean
Garber et al
(2007)79
N N N Y Y (2) S N ITT Adj mean
Garber et al
(2008)80
N N N Y Y (5) S N ITT Adj mean
Adj adjusted; BMI body mass index; FPG fasting plasma glucose; GLIM glimepiride; GLY glyburide; ITT intent to treat; LS least squares; METmetformin; NG not given; NI noninferiority; N
 No; OAD  oral antidiabetes drug; P  pooled; PIO  pioglitazone; PP  per protocol; QM  once monthly; QW  once weekly; ROSI  rosiglitazone; S, superiority; Y  yes.
*Abstract; no article published to date.
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Clinical TherapeuticsSupplemental Table IV. Analysis of heterogeneity (%) of the studies included in the present meta-analysis of the
glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl-peptidase IV
(DPP-4) inhibitors in type 2 diabetes mellitus (based on I2 statistics).
Drug
HbA1c Heterogeneity FPG Heterogeneity Body Weight Heterogeneity
Highest
Maintenance doses
All
Labeled Doses
Highest
Maintenance Doses
All
Labeled Doses
Highest
Maintenance Doses
All
Labeled Doses
GLP-1RAs
Exenatide QW 57.12 57.12 0 0 61.39 61.39
Exenatide BID 88.54 93.14 81.17 86.71 92.46 93.69
Liraglutide
once daily 81.74 91.51 63.51 91.02 92.27 97.21
DPP-4 inhibitors
Alogliptin 63.63 76.58 70.48 86.15 90.59 94.73
Linagliptin 93.99 93.99 96.24 96.24 NG NG
Saxagliptin 83.85 83.85 80.90 80.90 84.08 84.08
Sitagliptin 89.10 89.10 68.55 68.55 92.42 92.42
Vildagliptin 98.30 98.16 97.04 97.46 93.75 91.70
FPG  fasting plasma glucose; HbA1c  hemoglobin A1c; NG  not given.1258.e18 Volume 34 Number 6
V.R. Aroda et al.–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Zinman 2007
Sowa 2010
Nauck 2007a
Moretto 2008
Liutkus 2010
Kendall 2005
Kadowaki 2011
Kadowaki 2009
Heine 2005
Gao 2009
Gallwitz 2011a
Forti 2008
Drucker 2008
DeFronzo 2005
Buse 2009
Buse 2004
Bolli 2010
Blevins 2011
Bergenstal 2009
Mean HbA1c Difference (95% CI)
–0.86 [–1.08 to –0.64]
HbA1c Change (%)
–1.10 [–1.22 to –0.99]
–0.79 [–0.95 to –0.63]
–1.15 [–1.29 to –1.01]
–1.75 [–2.08 to –1.42]
–1.60 [–1.80 to –1.40]
–1.04 [–1.18 to –0.90]
–0.90 [–1.10 to –0.70]
–1.11 [–1.25 to –0.97]
–1.20 [–1.30 to –1.10]
–1.50 [–1.70 to –1.30]
–1.40 [–1.00 to –1.20]
–0.78 [–0.98 to –0.58]
–0.77 [–0.93 to –0.61]
–0.90 [–1.10 to –0.70]
–1.00 [–1.19 to –0.81]
–1.62 [–1.84 to –1.40]
–0.84 [–1.23 to –0.45]
–0.89 [–1.07 to –0.71]
–0.98 [–1.14 to –0.83]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
MacConell 2011
Kim 2007
Drucker 2008
Diamant 2010
Cuddihy 2011
Blevins 2011
Bergenstal 2010a
Mean HbA1c Difference (95% CI)
–1.59 [–1.70 to –1.48]
–1.90 [–2.10 to –1.70]
–1.70 [–2.29 to –1.11]
–1.50 [–1.89 to –1.11]
HbA1c Change (%)
–1.50 [–1.70 to –1.30]
–1.60 [–1.80 to –1.40]
–1.53 [–1.67 to –1.39]
–1.50 [–1.60 to –1.40]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Zinman 2009
Yang 2011a
Russell–Jones 2009
Pratley 2010
Nauck 2009
Marre 2009
Garber 2009
Buse 2009
Mean HbA1c Difference (95% CI)
–1.12 [–1.28 to –0.96]
HbA1c Change (%)
–1.33 [–1.51 to –1.15]
–1.27 [–1.41 to –1.13]
–1.50 [–1.70 to –1.30]
–1.10 [–1.27 to –0.93]
–1.00 [–1.20 to –0.80]
–1.14 [–1.30 to –0.99]
–1.50 [–1.63 to –1.37]
–1.45 [–1.64 to –1.26]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Pratley 2009b
Pratley 2009a
Nauck 2009
Fleck 2009
DeFronzo 2008
Mean HbA1c Difference (95% CI)
–0.59 [–0.84 to –0.34]
HbA1c Change (%)
–0.80 [–1.00 to –0.60]
–0.52 [–0.72 to –0.32]
–0.60 [–0.80 to –0.40]
–0.96 [–1.18 to –0.74]
–0.69 [–0.85 to –0.54]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Taskinen 2011
Owens 2010
Lewin 2010
Kawamori 2010a
Gomis 2011
Gallwitz 2011b
Forst 2010
Del Prato 2011
Mean HbA1c Difference (95% CI)
HbA1c Change (%)
–0.40 [–0.48 to –0.32]
–1.06 [–1.18 to –0.94]
–0.87 [–1.02 to –0.72]
–0.47 [–0.61 to –0.33]
–0.62 [–0.69 to –0.55]
–0.50 [–0.70 to –0.30]
–0.49 [–0.57 to –0.41]
–0.44 [–0.54 to –0.34]
–0.60 [–0.75 to –0.46]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Scheen 2010
Rosenstock 2009
Rosenstock 2008
Göke 2010
Fonseca 2011a
DeFronzo 2009
Chacra 2009
–0.88 [–1.01 to –0.75]
HbA1c Change (%)
Mean HbA1c Difference (95% CI)
–0.68 [–0.78 to –0.57]
–0.90 [–1.17 to –0.63]
–0.69 [–0.83 to –0.55]
–0.46 [–0.62 to –0.30]
–0.64 [–0.74 to –0.54]
–0.74 [–0.81 to –0.67]
–0.52 [–0.60 to –0.44]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Yang 2011b
Seck 2010
Scott 2008
Scheen 2010
Rosenstock 2011
Rosenstock 2006
Raz 2008
Raz 2006
Pratley 2010
Nonaka 2008
Nauck 2007b
Mohan 2009
Iwamoto 2010
Hermansen 2007 
Hanefeld 2007
Goldstein 2007
Fonseca 2011b
Cuddihy 2011
Charbonnel 2006
Bergenstal 2010b
Bergenstal 2010a
Aschner 2010
Aschner 2006
Arechavaleta 2011
–0.82 [–0.95 to –0.69]
HbA1c Change (%)
–0.48 [–0.61 to –0.35]
–0.85 [–0.98 to –0.72]
–0.69 [–0.81 to –0.57]
–0.73 [–0.87 to –0.59]
–0.67 [–0.75 to –0.60]
–1.00 [–1.30 to –0.70]
–0.65 [–0.80 to –0.50]
–0.67 [–0.75 to –0.59]
–0.45 [–0.57 to –0.33]
–0.44 [–0.58 to –0.30]
–0.66 [–0.83 to –0.49]
–0.67 [–0.77 to –0.57]
–0.47 [–0.55 to –0.39]
Mean HbA1c Difference (95% CI)
–0.61 [–0.74 to –0.48]
–0.43 [–0.48 to –0.38]
–0.89 [–1.00 to –0.78]
–1.15 [–1.31 to –0.99]
–0.70 [–0.84 to –0.58]
–0.70 [–0.80 to –0.60]
–0.90 [–1.03 to –0.77]
–0.45 [–0.65 to –0.25]
–0.62 [–0.69 to –0.55]
–0.54 [–0.64 to –0.44]
–0.90 [–1.10 to –0.70]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Garber 2007
Filozof 2010
Bosi 2009
Bosi 2007
Bolli 2008
Mean HbA1c Difference (95% CI)
HbA1c Change (%)
–0.88 [–0.98 to –0.78]
–1.70 [–1.78 to –1.62]
–0.90 [–1.10 to –0.70]
–0.81 [–0.93 to –0.69]
–1.00 [–1.20 to –0.80]
–1.06 [–1.48 to –0.64]
Exenatide BID
Exenatide QW
Liraglutide
Linagliptin
Alogliptin
GLP-1RAs DPP-4 Inhibitors
Saxagliptin
Sitagliptin
Vildagliptin
Supplemental Figure 1. Changes from baseline in hemoglobin (Hb) A1c in the analysis of highest maintenance
dose in the present meta-analysis of the glucagon-like peptide 1 receptor agonists (GLP-
1RAs) and dipeptidyl-peptidase IV (DPP-4) inhibitors in type 2 diabetes mellitus.June 2012 1258.e19
Clinical Therapeutics–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Zinman 2007
Sowa 2010
Nauck 2007a
Moretto 2008
Liutkus 2010
Kendall 2005
Kadowaki 2011
Kadowaki 2009
Heine 2005
Gao 2009
Gallwitz 2011a
Forti 2008
Drucker 2008
DeFronzo 2005
Buse 2009
Buse 2004
Bolli 2010
Blevins 2011
Bergenstal 2009
Mean HbA1C Difference (95% CI)
–0.98 [–1.14 to –0.82]
HbA1C Change (%)
–1.05 [–1.19 to –0.92]
–0.66 [–0.82 to –0.50]
–1.50 [–1.70 to –1.30]
–1.75 [–2.08 to –1.42]
–1.45 [–1.59 to –1.31]
–1.04 [–1.18 to –0.90]
–0.84 [–1.23 to –0.45]
–1.20 [–1.30 to –1.10]
–1.00 [–1.19 to –0.81]
–0.61 [–0.76 to –0.47]
–1.11 [–1.24 to –0.98]
–0.79 [–0.95 to –0.63]
–1.47 [–1.62 to –1.31]
–0.90 [–1.10 to –0.70]
–1.15 [–1.29 to –1.01]
–1.30 [–1.44 to –1.16]
–0.66 [–0.76 to –0.56]
–0.89 [–1.07 to –0.71]
–0.80 [–0.94 to –0.66]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
MacConell 2011
Kim 2007
Drucker 2008
Diamant 2010
Cuddihy 2011
Blevins 2011
Bergenstal 2010a
Mean HbA1C Difference (95% CI)
–1.59 [–1.70 to –1.48]
–1.90 [–2.10 to –1.70]
–1.70 [–2.29 to –1.11]
–1.50 [–1.89 to –1.11]
HbA1C Change (%)
–1.50 [–1.70 to –1.30]
–1.60 [–1.80 to –1.40]
–1.53 [–1.67 to –1.39]
–1.50 [–1.60 to –1.40]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Zinman 2009
Yang 2011a
Russell–Jones 2009
Pratley 2010
Nauck 2009
Marre 2009
Madsbad 2004
Kaku 2010
Garber 2009
Buse 2009
Mean HbA1C Difference (95% CI)
–1.12 [–1.28 to –0.96]
HbA1C Change (%)
–0.90 [–1.01 to –0.79]
–1.31 [–1.41 to –1.21]
–1.33 [–1.51 to –1.15]
–1.51 [–1.65 to –1.37]
–0.70 [–1.14 to –0.26]
–0.99 [–1.10 to –0.88]
–1.10 [–1.22 to –0.98]
–1.37 [–1.46 to –1.28]
–1.50 [–1.64 to –1.36]
–1.21 [–1.35 to –1.06]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Pratley 2009b
Pratley 2009a
Nauck 2009
Fleck 2009
DeFronzo 2008
Mean HbA1C Difference (95% CI)
–0.57 [–0.75 to –0.40]
HbA1C Change (%)
–0.73 [–0.87 to –0.59]
–0.45 [–0.59 to –0.31]
–0.60 [–0.74 to –0.46]
–0.96 [–1.18 to –0.74]
–0.65 [–0.80 to –0.50]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Taskinen 2011
Owens 2010
Lewin 2010
Kawamori 2010a
Gallwitz 2011
Gomis 2011
Forst 2010
DelPrato 2011
Mean HbA1C Difference (95% CI)
HbA1C Change (%)
–1.06 [–1.18 to –0.94]
–0.40 [–0.48 to –0.32]
–0.87 [–1.02 to –0.72]
–0.47 [–0.61 to –0.33]
–0.62 [–0.69 to –0.55]
–0.50 [–0.70 to –0.30]
–0.49 [–0.57 to –0.41]
–0.44 [–0.54 to –0.34]
–0.60 [–0.75 to –0.46]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Scheen 2010
Rosenstock 2009
Rosenstock 2008
Göke 2010
Fonseca 2011a
DeFronzo 2009
Chacra 2009
–0.88 [–1.01 to –0.75]
HbA1C Change (%)
Mean HbA1C Difference (95% CI)
–0.68 [–0.78 to –0.57]
–0.90 [–1.17 to –0.63]
–0.69 [–0.83 to –0.55]
–0.46 [–0.62 to –0.31]
–0.64 [–0.74 to –0.54]
–0.74 [–0.81 to –0.67]
–0.52 [–0.60 to –0.44]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Yang 2011b
Seck 2010
Scott 2008
Scheen 2010
Rosenstock 2011
Rosenstock 2006
Raz 2008
Raz 2006
Pratley 2010
Nonaka 2008
Nauck 2007b
Mohan 2009
Iwamoto 2010
Hermansen 2007
Hanefeld 2007
Goldstein 2007
Fonseca 2011b
Cuddihy 2011
Charbonnel 2006
Bergenstal 2010b
Bergenstal 2010a
Aschner 2010
Aschner 2006
Arechavaleta 2011
–0.82 [–0.95 to –0.69]
HbA1C Change (%)
–0.48 [–0.61 to –0.35]
–0.85 [–0.98 to –0.72]
–0.69 [–0.81 to –0.57]
–0.73 [–0.87 to –0.59]
–0.67 [–0.75 to –0.60]
–1.00 [–1.30 to –0.70]
–0.65 [–0.80 to –0.50]
–0.67 [–0.75 to –0.59]
–0.45 [–0.57 to –0.33]
–0.44 [–0.58 to –0.30]
–0.66 [–0.83 to –0.49]
–0.67 [–0.77 to –0.57]
–0.47 [–0.55 to –0.39]
Mean HbA1C Difference (95% CI)
–0.61 [–0.74 to –0.48]
–0.43 [–0.48 to –0.38]
–0.89 [–1.00 to –0.78]
–1.15 [–1.31 to –0.99]
–0.70 [–0.84 to –0.56]
–0.70 [–0.80 to –0.60]
–0.90 [–1.03 to –0.77]
–0.45 [–0.65 to –0.25]
–0.62 [–0.69 to –0.55]
–0.54 [–0.64 to –0.44]
–0.90 [–1.10 to –0.70]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Garber 2008
Bosi 2007
Bolli 2008
Garber 2007
Filozof 2010
Bosi 2009
Mean HbA1C Difference (95% CI)
HbA1C Change (%)
–0.88 [–0.98 to –0.78]
–1.70 [–1.78 to –1.62]
–0.90 [–1.10 to –0.70]
–0.81 [–0.93 to –0.69]
–1.00 [–1.20 to –0.80]
–0.98 [–1.37 to –0.59]
–0.58 [–0.78 to –0.38]
Exenatide BID
Exenatide QW
Liraglutide
Linagliptin
Alogliptin
Saxagliptin
Sitagliptin
Vildagliptin
GLP-1RAs DPP-4 Inhibitors
Supplemental Figure 2. Reductions in hemoglobin (Hb) A1c for all doses in the present meta-analysis of the
glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl-peptidase IV
(DPP-4) inhibitors in type 2 diabetes mellitus.1258.e20 Volume 34 Number 6
V.R. Aroda et al.–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Zinman 2007
Nauck 2007a
Moretto 2008
Kendall 2005
Kadowaki 2011
Kadowaki 2009
Heine 2005
Gao 2009
Forti 2008
Drucker 2008
DeFronzo 2005
Buse 2009
Buse 2004
Bolli 2010
Blevins 2011
Bergenstal 2009
Mean FPG Difference (95% CI)
–1.81 [–2.18 to –1.44]
FPG (mmol/L)
–1.16 [–1.35 to –0.97]
–0.60 [–1.19 to –0.01]
–1.40 [–1.79 to –1.01]
–1.19 [–1.26 to –1.12]
–1.82 [–2.21 to –1.42]
–1.04 [–1.47 to –0.60]
–1.43 [–1.72 to –1.13]
–1.30 [–1.60 to –1.00]
–0.56 [–1.04 to –0.08]
–1.60 [–2.25 to –0.96]
–0.60 [–0.99 to –0.21]
–1.61 [–2.02 to –1.20]
–0.67 [–1.21 to –0.12]
–0.60 [–0.90 to –0.29]
–0.60 [–0.99 to –0.21]
–1.59 [–2.02 to –1.16]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
MacConell 2011
Kim 2007
Drucker 2008
Diamant 2010
Cuddihy 2011
Blevins 2011
Bergenstal 2010a
Mean FPG Difference (95% CI)
–2.12 [–2.28 to –1.96]
–2.30 [–2.69 to –1.91]
–2.20 [–3.18 to –1.22]
–1.89 [–2.87 to –0.91]
FPG (mmol/L)
–1.80 [–2.20 to –1.40]
–1.94 [–2.49 to –1.40]
–2.25 [–2.52 to –1.98]
–2.10 [–2.49 to –1.71]
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
All
Zinman 2009
Yang 2011a
Russell–Jones 2009
Pratley 2010
Nauck 2009
Marre 2009
Garber 2009
Buse 2009
Mean FPG Difference (95% CI)
–1.61 [–2.00 to –1.22]
FPG (mmol/L)
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Supplemental Figure 3. Changes from baseline in fasting plasma glucose (FPG) in the analysis of highest main-
tenance dose in the present meta-analysis of the glucagon-like peptide 1 receptor ago-
nists (GLP-1RAs) and dipeptidyl-peptidase IV (DPP-4) inhibitors in type 2 diabetes
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Supplemental Figure 4. Changes from baseline in weight in the analysis of highest maintenance dose in the
present meta-analysis of the glucagon-like peptide 1 receptor agonists (GLP-1RAs) and
dipeptidyl-peptidase IV (DPP-4) inhibitors in type 2 diabetes mellitus.1258.e22 Volume 34 Number 6
